We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Surrozen, Inc. (SRZN - Free Report) shares rallied 5.9% in the last trading session to close at $29.86. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.9% gain over the past four weeks.
Surrozen’s stock price gain reflects rising investor confidence driven by progress in its Wnt signaling–based ophthalmology pipeline, which includes multiple early-stage biologics targeting serious retinal diseases. The company is advancing its lead candidates, SZN-8141 and SZN-8143, for retinal diseases and remains on track to file an investigational new drug application for SZN-8141 in the second half of 2026. Additionally, its partnered program SZN-413 achieved a key milestone with Boehringer Ingelheim following positive IND-enabling GLP toxicology study data, triggering a $5 million payment to Surrozen under their agreement.
This company is expected to post quarterly loss of $1.39 per share in its upcoming report, which represents a year-over-year change of +55.6%. Revenues are expected to be $5 million, up 410.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Surrozen, the consensus EPS estimate for the quarter has been revised 4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on SRZN going forward to see if this recent jump can turn into more strength down the road.
Surrozen is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, United Therapeutics (UTHR - Free Report) , finished the last trading session 1% higher at $577.63. UTHR has returned 6.6% over the past month.
United Therapeutics' consensus EPS estimate for the upcoming report has changed +0.3% over the past month to $6.7. Compared to the company's year-ago EPS, this represents a change of +1.1%. United Therapeutics currently boasts a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?
Surrozen, Inc. (SRZN - Free Report) shares rallied 5.9% in the last trading session to close at $29.86. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.9% gain over the past four weeks.
Surrozen’s stock price gain reflects rising investor confidence driven by progress in its Wnt signaling–based ophthalmology pipeline, which includes multiple early-stage biologics targeting serious retinal diseases. The company is advancing its lead candidates, SZN-8141 and SZN-8143, for retinal diseases and remains on track to file an investigational new drug application for SZN-8141 in the second half of 2026. Additionally, its partnered program SZN-413 achieved a key milestone with Boehringer Ingelheim following positive IND-enabling GLP toxicology study data, triggering a $5 million payment to Surrozen under their agreement.
This company is expected to post quarterly loss of $1.39 per share in its upcoming report, which represents a year-over-year change of +55.6%. Revenues are expected to be $5 million, up 410.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Surrozen, the consensus EPS estimate for the quarter has been revised 4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on SRZN going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Surrozen is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, United Therapeutics (UTHR - Free Report) , finished the last trading session 1% higher at $577.63. UTHR has returned 6.6% over the past month.
United Therapeutics' consensus EPS estimate for the upcoming report has changed +0.3% over the past month to $6.7. Compared to the company's year-ago EPS, this represents a change of +1.1%. United Therapeutics currently boasts a Zacks Rank of #3 (Hold).